Journal Mobile Options
Table of Contents
Vol. 56, No. 4, 2007
Issue release date: April 2008
Neuropsychobiology 2007;56:185–190
(DOI:10.1159/000120623)

Blood Levels of Brain-Derived Neurotrophic Factor Correlate with Several Psychopathological Symptoms in Anorexia Nervosa Patients

Mercader J.M. · Fernández-Aranda F. · Gratacòs M. · Ribasés M. · Badía A. · Villarejo C. · Solano R. · González J.R. · Vallejo J. · Estivill X.
aGenes and Disease Program, Center for Genomic Regulation (CRG), and CIBER en Epidemiología y Salud Pública (CIBERESP), bDepartment of Psychiatry, University Hospital of Bellvitge, L’Hospitalet de Llobregat and CIBER Fisiopatologia Obesidad y Nutricion (CIBEROBN), Instituto Salud Carlos III., cBarcelona Node, National Genotyping Center (CEGEN), Center for Genomic Regulation, dDepartment of Psychiatry, Hospital Universitari Vall d’Hebron, and eExperimental and Health Sciences Department, Pompeu Fabra University, Barcelona, Spain

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Evidence of a role of brain-derived neurotrophic factor (BDNF) in the pathophysiology of eating disorders (ED) has been provided by association studies and by murine models. BDNF plasma levels have been found altered in ED and in psychiatric disorders that show comorbidity with ED. Aims: Since the role of BDNF levels in ED-related psychopathological symptoms has not been tested, we investigated the correlation of BDNF plasma levels with the Symptom Checklist 90 Revised (SCL-90R) questionnaire in a total of 78 ED patients. Methods: BDNF levels, measured by the enzyme-linked immunoassay system, and SCL-90R questionnaire, were assessed in a total of 78 ED patients. The relationship between BDNF levels and SCL-90R scales was calculated using a general linear model. Results: BDNF plasma levels correlated with the Global Severity Index and the Positive Symptom Distress Index global scales and five of the nine subscales in the anorexia nervosa patients. BDNF plasma levels were able to explain, in the case of the Psychoticism subscale, up to 17% of the variability (p = 0.006). Conclusion: Our data suggest that BDNF levels could be involved in the severity of the disease through the modulation of psychopathological traits that are associated with the ED phenotype.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Fairburn CG, Harrison PJ: Eating disorders. Lancet 2003;361:407–416.
  2. Ribases M, Gratacos M, Armengol L, de Cid R, Badia A, Jimenez L, Solano R, Vallejo J, Fernandez F, Estivill X: Met66 in the brain-derived neurotrophic factor (BDNF) precursor is associated with anorexia nervosa restrictive type. Mol Psychiatry 2003;8:745–751.
  3. Ribases M, Gratacos M, Fernandez-Aranda F, Bellodi L, Boni C, Anderluh M, Cavallini MC, Cellini E, Di Bella D, Erzegovesi S, Foulon C, Gabrovsek M, Gorwood P, Hebebrand J, Hinney A, Holliday J, Hu X, Karwautz A, Kipman A, Komel R, Nacmias B, Remschmidt H, Ricca V, Sorbi S, Wagner G, Treasure J, Collier DA, Estivill X: Association of BDNF with anorexia, bulimia and age of onset of weight loss in six European populations. Hum Mol Genet 2004;13:1205–1212.
  4. Nakazato M, Hashimoto K, Shimizu E, Kumakiri C, Koizumi H, Okamura N, Mitsumori M, Komatsu N, Iyo M: Decreased levels of serum brain-derived neurotrophic factor in female patients with eating disorders. Biol Psychiatry 2003;54:485–490.
  5. Koizumi H, Hashimoto K, Itoh K, Nakazato M, Shimizu E, Ohgake S, Koike K, Okamura N, Matsushita S, Suzuki K, Murayama M, Higuchi S, Iyo M: Association between the brain-derived neurotrophic factor 196G/A polymorphism and eating disorders. Am J Med Genet 2004;127B:125–127.

    External Resources

  6. Hashimoto K, Koizumi H, Nakazato M, Shimizu E, Iyo M: Role of brain-derived neurotrophic factor in eating disorders: recent findings and its pathophysiological implications. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:499–504.
  7. Gratacos M, Gonzalez JR, Mercader JM, de Cid R, Urretavizcaya M, Estivill X: Brain- derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry 2007;61:911–922.
  8. Ribases M, Gratacos M, Fernandez-Aranda F, Bellodi L, Boni C, Anderluh M, Cristina Cavallini M, Cellini E, Di Bella D, Erzegovesi S, Foulon C, Gabrovsek M, Gorwood P, Hebebrand J, Hinney A, Holliday J, Hu X, Karwautz A, Kipman A, Komel R, Nacmias B, Remschmidt H, Ricca V, Sorbi S, Tomori M, Wagner G, Treasure J, Collier DA, Estivill X: Association of BDNF with restricting anorexia nervosa and minimum body mass index: a family-based association study of eight European populations. Eur J Hum Genet 2005;13:428–434.
  9. Ribases M, Gratacos M, Badia A, Jimenez L, Solano R, Vallejo J, Fernandez-Aranda F, Estivill X: Contribution of NTRK2 to the genetic susceptibility to anorexia nervosa, harm avoidance and minimum body mass index. Mol Psychiatry 2005;10:851–860.
  10. Monteleone P, Fabrazzo M, Martiadis V, Serritella C, Pannuto M, Maj M: Circulating brain-derived neurotrophic factor is decreased in women with anorexia and bulimia nervosa but not in women with binge-eating disorder: relationships to co-morbid depression, psychopathology and hormonal variables. Psychol Med 2005;35:897–905.
  11. Mercader JM, Ribasés M, Gratacòs M, González JR, Bayés M, de Cid R, Badía A, Fernández-Aranda F, Estivill X: Altered brain-derived neurotrophic factor blood levels and gene variability are associated with anorexia and bulimia. Genes Brain Behav 2007;6:706–716.
  12. Bulik CM, Klump KL, Thornton L, Kaplan AS, Devlin B, Fichter MM, Halmi KA, Strober M, Woodside DB, Crow S, Mitchell JE, Rotondo A, Mauri M, Cassano GB, Keel PK, Berrettini WH, Kaye WH: Alcohol use disorder comorbidity in eating disorders: a multicenter study. J Clin Psychiatry 2004;65:1000–1006.
  13. Godart NT, Flament MF, Lecrubier Y, Jeammet P: Anxiety disorders in anorexia nervosa and bulimia nervosa: co-morbidity and chronology of appearance. Eur Psychiatry 2000;15:38–45.
  14. Grilo CM, Sanislow CA, Skodol AE, Gunderson JG, Stout RL, Shea MT, Zanarini MC, Bender DS, Morey LC, Dyck IR, McGlashan TH: Do eating disorders co-occur with personality disorders? Comparison groups matter. Int J Eat Disord 2003;33:155–164.
  15. Milos G, Spindler A, Schnyder U: Psychiatric comorbidity and Eating Disorder Inventory (EDI) profiles in eating disorder patients. Can J Psychiatry 2004;49:179–184.

    External Resources

  16. Kaye WH, Bulik CM, Thornton L, Barbarich N, Masters K: Comorbidity of anxiety disorders with anorexia and bulimia nervosa. Am J Psychiatry 2004;161:2215–2221.
  17. Steiger H, Gauvin L, Engelberg MJ, Ying Kin NM, Israel M, Wonderlich SA, Richardson J: Mood- and restraint-based antecedents to binge episodes in bulimia nervosa: possible influences of the serotonin system. Psychol Med 2005;35:1553–1562.
  18. Neumeister A, Yuan P, Young TA, Bonne O, Luckenbaugh DA, Charney DS, Manji H: Effects of tryptophan depletion on serum levels of brain-derived neurotrophic factor in unmedicated patients with remitted depression and healthy subjects. Am J Psychiatry 2005;162:805–807.
  19. Tan YL, Zhou DF, Cao LY, Zou YZ, Zhang XY: Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 2005;382:27–32.
  20. Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G: Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005;57:1068–1072.
  21. Monteleone P, Tortorella A, Martiadis V, Serritella C, Fuschino A, Maj M: Opposite changes in the serum brain-derived neurotrophic factor in anorexia nervosa and obesity. Psychosom Med 2004;66:744–748.
  22. Bulik CM, Tozzi F: Genetics in eating disorders: state of the science. CNS Spectr 2004;9:511–515.
  23. Fernandez-Aranda F, Jimenez-Murcia S, Alvarez-Moya EM, Granero R, Vallejo J, Bulik CM: Impulse control disorders in eating disorders: clinical and therapeutic implications. Compr Psychiatry 2006;47:482–488.
  24. Fernandez-Aranda F, Pinheiro AP, Tozzi F, Thornton LM, Fichter MM, Halmi KA, Kaplan AS, Klump KL, Strober M, Woodside DB, Crow S, Mitchell J, Rotondo A, Keel P, Plotnicov KH, Berrettini WH, Kaye WH, Crawford SF, Johnson C, Brandt H, La Via M, Bulik CM: Symptom profile of major depressive disorder in women with eating disorders. Aust NZ J Psychiatry 2007;41:24–31.
  25. McDermott B, Forbes D, Harris C, McCormack J, Gibbon P: Non-eating disorders psychopathology in children and adolescents with eating disorders: implications for malnutrition and symptom severity. J Psychosom Res 2006;60:257–261.
  26. Ro O, Martinsen EW, Hoffart A, Rosenvinge JH: Short-term follow-up of adults with long standing anorexia nervosa or non-specified eating disorder after inpatient treatment. Eat Weight Disord 2004;9:62–68.
  27. First M, Gibbon M, Spitzer R, J W: Users Guide for the Structured Clinical Interview for DSM IV Axis I Disorders, research version (SCID-I, version 2.0). New York, New York State Psychiatric Institute, 1996.
  28. Derogatis LR, Melisaratos N: The Brief Symptom Inventory: an introductory report. Psychol Med 1983;13:595–605.
  29. Derogatis LR: A Bibliography of Research Reports 1975–1990. Baltimore, Clinical Psychometric Research, 1990.
  30. Derogatis LR: Cuestionario de 90 síntomas: Manual. Madrid, TEA Editorial, 2002.
  31. Verona E, Sachs-Ericsson N, Joiner TE Jr: Suicide attempts associated with externalizing psychopathology in an epidemiological sample. Am J Psychiatry 2004;161:444–451.
  32. Association AP: DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. Washington, The American Psychiatric Association, 1994.
  33. Fassino S, Abbate-Daga G, Amianto F, Leombruni P, Boggio S, Rovera GG: Temperament and character profile of eating disorders: a controlled study with the Temperament and Character Inventory. Int J Eat Disord 2002;32:412–425.
  34. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M: Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003;54:70–75.
  35. Aydemir O, Deveci A, Taneli F: The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:261–265.
  36. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM: Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002;109:143–148.
  37. Lang UE, Hellweg R, Gallinat J: BDNF serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychopharmacology 2004;29:795–798.
  38. Jimenez-Murcia S, Fernandez-Aranda F, Raich RM, Alonso P, Krug I, Jaurrieta N, Alvarez-Moya E, Labad J, Menchon JM, Vallejo J: Obsessive-compulsive and eating disorders: comparison of clinical and personality features. Psychiatry Clin Neurosci 2007;61:385–391.
  39. Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, Virchow JC: The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 2005;26:115–123.
  40. Donovan MJ, Miranda RC, Kraemer R, McCaffrey TA, Tessarollo L, Mahadeo D, Sharif S, Kaplan DR, Tsoulfas P, Parada L, et al: Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. Am J Pathol 1995;147:309–324.
  41. Braun A, Lommatzsch M, Mannsfeldt A, Neuhaus-Steinmetz U, Fischer A, Schnoy N, Lewin GR, Renz H: Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation. Am J Respir Cell Mol Biol 1999;21:537–546.
  42. Nakahashi T, Fujimura H, Altar CA, Li J, Kambayashi J, Tandon NN, Sun B: Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett 2000;470:113–117.
  43. Gielen A, Khademi M, Muhallab S, Olsson T, Piehl F: Increased brain-derived neurotrophic factor expression in white blood cells of relapsing-remitting multiple sclerosis patients. Scand J Immunol 2003;57:493–497.
  44. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, Kolbeck R, Hoppe E, Oropeza-Wekerle RL, Bartke I, Stadelmann C, Lassmann H, Wekerle H, Hohlfeld R: Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999;189:865–870.
  45. Karege F, Schwald M, Cisse M: Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002;328:261–264.
  46. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ: Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998;37:1553–1561.
  47. Phillips HS, Hains JM, Laramee GR, Rosenthal A, Winslow JW: Widespread expression of BDNF but not NT3 by target areas of basal forebrain cholinergic neurons. Science 1990;250:290–294.
  48. Fujimura H, Altar CA, Chen R, Nakamura T, Nakahashi T, Kambayashi J, Sun B, Tandon NN: Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 2002;87:728–734.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50